论文部分内容阅读
肝细胞肝癌是肝细胞原发性恶性肿瘤,具有发现晚、死亡率高等特点。分子靶向药物如酪氨酸激酶抑制剂极有希望成为肝癌治疗药物,目前已引起特别关注,研究者已对酪氨酸激酶受体抑制剂进行了深入研究。本文对多种酪氨酸激酶受体作用于肝癌细胞的机制以及肿瘤细胞内在和外在的抵消激酶抑制剂作用的机制进行了讨论,同时对目前多靶标激酶抑制剂抗肝癌药物的优越性和可行性及其临床研究进展进行综述和展望。
Hepatocellular carcinoma is a primary malignant tumor of hepatocytes, with the characteristics of late detection and high mortality. Molecular targeted drugs such as tyrosine kinase inhibitors are promising drugs for the treatment of hepatocellular carcinoma and have drawn special attention so far. Researchers have conducted in-depth studies on tyrosine kinase receptor inhibitors. In this paper, the mechanism of multiple tyrosine kinase receptors acting on hepatocellular carcinoma cells and the mechanism of counteracting the intrinsic and extrinsic cancerogenic kinase inhibitors in tumor cells are discussed. At the same time, the current multi-target kinase inhibitors anti-hepatoma drug superiority and Feasibility and clinical progress of the review and outlook.